International journal of women's health · 2026
Global Burden of Polycystic Ovary Syndrome: A Systematic Analysis of Pre- and Post-Pandemic Trends from the 2021 Global Burden of Disease Study (1990-2021).
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guo Yingwu, Du Yingrong, Zhang Lingfang, Xu Huihui, Liu Jun, Li Shenghao, Xu Zhaoyuan, Yan Junfang, Chen Jie, Wang Huawei
Аннотация
OBJECTIVE: The study systematically examines the long-term trends in the global burden of Polycystic ovary syndrome (PCOS) across 204 countries and territories, with a specific focus on comparing pre-pandemic (1990-2019) and post-pandemic (2019-2021) periods.
METHODS: Using data from the Global Burden of Disease (GBD) 2021 for women aged 15-54, we estimated incidence, prevalence, and years lived with disability (YLDs). Age-standardized rates (ASIR, ASPR, ASYR) and estimated annual percentage change (EAPC) were calculated. Joinpoint, Age-Period-Cohort, and Bayesian models were used to analyze trends from 1990-2021 and project burden to 2050. Mendelian randomization (MR) assessed whether anxiety and guilt contribute to PCOS risk.
RESULTS: All burden measures increased globally from 1990 to 2021. Post-2019, the rate of increase (EAPC) accelerated significantly compared to the pre-pandemic period. High-SDI regions showed the lowest pre-pandemic growth but the largest increases during the pandemic. Health inequalities modestly improved by 2021. Projections indicate continued growth, with ASIR, ASPR, and ASYR reaching 73.66, 2104.41, and 18.37 per 100,000 by 2050, respectively. MR supports anxiety and guilt as likely risk factors.
CONCLUSION: The post-pandemic rise in PCOS burden underscores systemic vulnerabilities in women's endocrine healthcare during health emergencies and signals a growing global health challenge.
METHODS: Using data from the Global Burden of Disease (GBD) 2021 for women aged 15-54, we estimated incidence, prevalence, and years lived with disability (YLDs). Age-standardized rates (ASIR, ASPR, ASYR) and estimated annual percentage change (EAPC) were calculated. Joinpoint, Age-Period-Cohort, and Bayesian models were used to analyze trends from 1990-2021 and project burden to 2050. Mendelian randomization (MR) assessed whether anxiety and guilt contribute to PCOS risk.
RESULTS: All burden measures increased globally from 1990 to 2021. Post-2019, the rate of increase (EAPC) accelerated significantly compared to the pre-pandemic period. High-SDI regions showed the lowest pre-pandemic growth but the largest increases during the pandemic. Health inequalities modestly improved by 2021. Projections indicate continued growth, with ASIR, ASPR, and ASYR reaching 73.66, 2104.41, and 18.37 per 100,000 by 2050, respectively. MR supports anxiety and guilt as likely risk factors.
CONCLUSION: The post-pandemic rise in PCOS burden underscores systemic vulnerabilities in women's endocrine healthcare during health emergencies and signals a growing global health challenge.